11:15 AM EDT, 06/03/2024 (MT Newswires) -- Neurogene ( NGNE ) said Monday that the US Food and Drug Administration selected the company's NGN-401 gene therapy for Rett syndrome for the support for clinical trials advancing rare disease therapeutics pilot program.

Neurogene ( NGNE ) said it will have enhanced communications with the FDA to accelerate NGN-401 development as part of the program.

Neurogene ( NGNE ) said it is evaluating two dose levels of the gene therapy candidate in a phase 1/2 study.

Price: 37.75, Change: +0.15, Percent Change: +0.40